Severe or prolonged inflammatory response caused by infection or biomaterials leads to delayed healing or bone repair failure. This study investigated the important roles of the proinflammatory cytokines of the interleukin-12 (IL-12) family, namely, IL-12 and IL-23, in the inflammation-mediated inhibition of bone formation in vivo. IL-12p40 −/− mice lacking IL-12 and IL-23 exhibited enhanced bone formation. IL-12 and IL-23 indirectly inhibited bone marrow mesenchymal stem cell (BMMSC) differentiation by stimulating CD4 + T cells to increase interferon γ (IFN-γ) and IL-17 levels. Mechanistically, IL-17 synergistically enhanced IFN-γ-induced BMMSC apoptosis. Moreover, INF-γ and IL-17 exerted proapoptotic effects by upregulating the expression levels of Fas and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), as well as by activating the caspase cascade in BMMSCs. IL-12p40 depletion in mice could promote ectopic bone formation. Thus, IL-12p40 is an attractive therapeutic target to overcome the inflammation-mediated inhibition of bone formation in vivo.
Approximately 7.9 million fractures occur in the United States each year. Although most heal normally, 5-20% of fractures result in delayed or impaired healing requiring therapeutic intervention. 1 Bone marrow mesenchymal stem cell (BMMSC)-based therapy is an attractive option for augmenting the fracture repair process and BMMSCs have been used for the treatment of fracture non-union in clinical studies, 2, 3 because of their fast and easy purification, amplification, multipotent differentiation ability, and low immunogenicity. 4, 5 However, 10-18% of fractures stayed non-union after stem cell therapy in early clinical reports. 6 Patients suffering from non-union must undergo a second surgery, which may increase the economic burden on families, prolong the pain, and impaired the quality of life and work. 7 Inflammation is an important regulator of bone regeneration. 8, 9 Following fracture injury, there is an initial inflammatory response that has a crucial role in bone healing. 1, 10 However, severe or prolonged inflammatory response leads to delayed healing or bone repair failure. 11 Recent studies have shown that proinflammatory cytokines can impair bone repair in local injury. Interleukin-1β (IL-1β) suppresses matrix mineralization and osteoblastic marker gene expression in vitro. 12 Tumor necrosis factor α (TNF-α) inhibits osteogenic differentiation 12 and reduces bone formation in nude mice. 13 IL-4 and interferon γ (IFN-γ) are also significantly antiosteogenic.
14 Moreover, IFN-γ and TNF-α synergistically induce BMMSC apoptosis and significantly inhibit bone formation in vivo. 13 Meanwhile, IL-17 stimulates the nuclear factor kappa B (NF-κB) signaling pathway and impairs the differentiation of BMMSCs. 15 Therefore, defining the crosstalk between proinflammatory cytokines and BMMSCs is an important goal of the newly emerging osteoimmunology field, and such insights may also be helpful for designing improved protocols for BMMSC-mediated bone repair and regeneration.
The combination of BMMSCs with a suitable scaffold is an effective approach in bone tissue engineering to treat and reconstruct large bone defects. 16 Materials implanted into a body initiate a host response, which leads to inflammation and foreign body reactions. 17 Given their individual differences, some patients exhibit severe immune responses that lead to bone regeneration failure. Understanding the inflammatory factors and signaling pathways that participate in the healing is highly significant for clinical treatments and for predicting the effects of restoration. T cells have an important role in fracture healing process. 18, 19 Intravenous infusion of pan T cells or CD4 + T cells blocks bone formation in nude mice. 13 IL-12 and IL-23 are proinflammatory cytokines of the IL-12 family that are secreted by dendritic cells and tissue-resident macrophages to facilitate T-cell differentiation. IL-12 and IL-23 share a common p40 subunit (encoded by the IL-12p40 gene). IL-12p40 has an important role in the development and progression of inflammation, and it can directly induce the development of T cells and enhance the production of immune factors. [20] [21] [22] Thus, IL-12 and IL-23 may have key roles in the inflammation-mediated inhibition of bone formation. However, the roles of the two cytokines in BMMSC-based bone regeneration are still poorly understood.
In the present study, we showed that deletion of IL-12 and IL-23 increased bone formation and bone mass in IL-12p40 13 Trauma and biomaterials can cause local inflammation. Thus, implanting BMMSCs mixed with biomaterials into C57BL/6J mice leads to the accumulation of a large number of immune factors around the implants. Severe inflammatory response affects bone repair. 13 We used an ectopic bone formation assay in C57BL/6J mice to detect the expression of immune factors in the implants. β-Tricalcium phosphate (β-TCP) is similar to bone in chemical composition and physical characteristics. Therefore, it has been widely used in clinical orthopedic surgery for almost 40 years. 23, 24 In this study, we used β-TCP as the scaffold. Initially, we found the expression of IL-12 and IL-23 in the BMMSC implants. Notably, the concentrations of IL-23 in the BMMSC implants were elevated at 7-21 days after BMMSC implantation in C57BL/6J mice ( Figure 1a ). To explore whether or not IL-12 and IL-23 influence bone formation in vivo, we used a mouse model with global deletion of IL-12p40 (B6.129S1-Il12b tm1Jm /J, IL-12p40 −/− ). The knockout mice lacked both IL-12 and IL-23. 21 Micro-computed tomography (Micro-CT) analysis of the left distal femur metaphysis revealed that the bone mineral density (BMD) and the bone volume/tissue volume ratio (BV/TV) of the IL-12p40 −/− mice were significantly higher than those of the wild-type (WT) mice (C57BL/6J) at 2 months of age (Figures 1b-d) . Trabecular thickness (Tb.Th) was also higher in the IL-12p40 −/− mice than in the WT mice (Figure 1e ), whereas trabecular spacing (Tb.Sp) was lower in the former than in the latter (Figure 1f ). Histologic analysis showed that the IL-12p40 −/− mice had more trabecular bone than the WT mice as indicated by hematoxylin and eosin (H&E) staining (Figure 1g ). In addition, histomorphometric analysis revealed more osteoblast surface ( Figure 1h ) and less osteoclast surface (Figure 1i ) in the 2-month-old IL-12p40 −/− mice than in the WT mice. We also assessed the serum osteocalcin (OCN) levels, a marker of bone formation, and found that serum OCN levels were significantly higher in the IL-12p40 −/− mice than in the WT mice (Figure 1j ). By contrast, the IL-12p40 −/− mice had lower serum concentrations of collagen type I cross-linked C-telopeptide (CTX-1), a marker of bone resorption (Figure 1k ). We performed dynamic histomorphometric analysis by using double calcein labeling to confirm further whether or not IL-12p40 −/− mice display increased bone formation and found a 1.63-fold increase in the mineral apposition rate (MAR) of the IL-12p40 −/− mice compared with that of the WT mice (Figure 1l) . Thus, the IL-12p40 −/− mice had increased bone formation and reduced bone resorption. These results suggest that IL-12 and IL-23 can inhibit BMMSC-osteoblast differentiation and bone formation in vivo.
CD4
+ T cells are needed for IL-12 and IL-23 to inhibit osteogenic differentiation of BMMSCs. The IL-12p40 −/− mice exhibited increased bone mass and bone formation. Therefore, we speculated that IL-12 and IL-23 directly inhibit BMMSC osteogenesis. To confirm this hypothesis, we subcutaneously implanted BMMSCs and β-TCP in nude mice with hydrogels to release IL-12 and IL-23. However, IL-12 and IL-23 treatments exerted no direct inhibitory effects on bone formation in vivo compared with the control mice (Figures 2a and b) .
Subsequently, we induced osteogenic differentiation of BMMSCs by culturing in osteogenic medium in vitro and adding different doses (10- These results prompted us to investigate whether or not IL-12 and IL-23 exert indirect effects on BMMSC differentiation. T cells have an important role in adaptive immunity, and naive T cells differentiate into T helper type 1 (Th1) and Th17 cells depending on IL-12 and IL-23, 25 respectively. IL-12 and IL-23 might indirectly inhibit osteogenic differentiation and bone formation because nude mice lack functioning T cells. 26 To confirm this hypothesis, we isolated mouse CD4 + T cells and treated them with IL-12 and IL-23. Then, we collected the culture supernatants and induced osteogenic differentiation of BMMSCs by culturing in osteogenic medium plus the supernatants. Interestingly, the osteogenesis of Figure 3d ). Furthermore, Alizarin Red S staining revealed that IFN-γ treatment inhibited osteogenesis in a dose-dependent manner (Figure 3e ). The expression levels of differentiation markers (Osx, OCN, and Col1) were also significantly reduced (Figure 3f ). The inhibitory effect of IFN-γ on osteoblast differentiation was stronger than those of IL-12p40 impairs MSC-mediated bone regeneration via CD4 + T cells Jiajia Xu et al IL-17 at the same concentration. Moreover, the combination of IFN-γ and IL-17 displayed stronger inhibition of osteogenesis compared with that of either cytokine alone, especially at high concentration levels (200 ng/ml) (Figures 3g and h ). Therefore, we treated BMMSCs with 200 ng/ml IFN-γ and 200 ng/ml IL-17 in all subsequent experiments. IL-17 slightly inhibited osteogenic differentiation, whereas IFN-γ strongly inhibited the expression of Runx2, ALP, Osx, OCN, and Col1. However, IL-17 could markedly amplify the inhibitory effect of INF-γ on osteogenesis (Figures 3i and j) . Taken together, these observations strongly suggest that IL-12 and IL-23 indirectly inhibit BMMSC osteogenic differentiation by increasing the expression of INF-γ and IL-17.
IL-17 synergistically enhances BMMSC apoptosis induced by IFN-γ. We learned that IL-17 significantly enhanced the inhibitory effect of INF-γ on osteogenesis. Therefore, we speculated that IFN-γ and IL-17 exert an additive effect on the osteoblast differentiation of BMMSCs. We first detected IFN-γ-and IL-17-related pathways and found that IL-17 activated the NF-κB (p65) and MAPK (p38 and JNK) pathways and that STAT1 was phosphorylated in response to IFN-γ (Figure 4a ). The combination of IFN-γ and IL-17 stimulation did not enhance the above-mentioned signaling pathways. By contrast, the p65, p38, and JNK signaling pathways were weakened compared with BMMSCs stimulated by IL-17 alone (Figure 4a) . Therefore, the effects of the combination of IFN-γ and IL-17 were not simply additive, and these data prompted us to examine other signaling pathways. IFN-γ reportedly induces apoptosis.
30,31
When we cultured BMMSCs with IL-17 or IFN-γ, IL-17 exerted no effect on cell death, but IFN-γ significantly induced BMMSC death in a dose-dependent manner. IFN-γ further caused BMMSC death in the presence of IL-17 ( Figure 4b) . To determine the effect of IL-17 on IFN-γ-induced cell death, we added 200 ng/ml IL-17 to BMMSCs that were treated with different doses of IFN-γ (ranging from 10 to 200 ng/ml). When IL-17 was added, only 10 ng/ml IFN-γ significantly enhanced BMMSC death (Figure 4c ). To confirm further the synergistic effects of IFN-γ and IL-17, we added 200 ng/ml IFN-γ to BMMSCs with 10-200 ng/ml IL-17. As expected, the elevated levels of IL-17 gradually increased BMMSC death when combined with IFN-γ (Figure 4d ). When the IL-17 concentration reached 200 ng/ml, the maximum number of BMMSCs killed was achieved (Figure 4d ). These data indicate that IL-17 can synergistically promote BMMSC death induced by IFN-γ.
We first added IFN-γ and IL-17 to BMMSCs and detected the expression of the Fas/Fas ligand (FasL), TNF-α/tumor necrosis factor receptor 1 (TNFR1), and TRAIL/death receptor 5 (DR5) at different time points to determine whether or not cells died by apoptosis. IL-17 did not increase the expression of Fas and TRAIL, whereas TRAIL expression was strongly induced in BMMSCs upon IFN-γ stimulation. However, the combination of IFN-γ and IL-17 further upregulated Fas and TRAIL expression in BMMSCs (Figures 4e and f) . In addition, western blot analysis showed that the combination of IFN-γ and IL-17 enhanced the activation of caspase 8 and caspase 3 (Figure 4g ). Then, we used TdT-mediated UTP nick end labeling (TUNEL) staining to detect apoptotic cells. IL-17 alone exerted no effect on apoptosis, whereas IFN-γ induced BMMSC apoptosis. Furthermore, the combination of IFN-γ and IL-17 had a higher apoptotic rate and a lower percentage of surviving cells than either cytokine alone (Figures 4h-j) . We immunostained cleaved caspase 3 in the implants to confirm further the apoptosis induced by IFN-γ and IL-17 in vivo.
Results revealed that caspase 3 activity decreased in the IL-12p40 −/− mice ( Figure 4k ). Consistent with activated caspase 3 staining, we found that TUNEL staining was also potently reduced in the IL-12p40 −/− mice ( Figure 4l ). These results indicate that IL-17 can synergistically enhance IFN-γ-induced BMMSC apoptosis in vitro and in vivo.
Suppression of caspase activation can partially rescue osteogenic differentiation of BMMSCs. We used small interfering RNA (siRNA) and caspase inhibitors to block apoptosis to test whether or not inhibiting the apoptotic pathways could rescue the effects of IFN-γ and IL-17 on BMMSC differentiation. First, we designed siRNA to inhibit Fas and TRAIL expression in BMMSCs (Figures 5a and b) . Knockdown of Fas or TRAIL expression in BMMSCs could block the activation of caspase 8 and caspase 3 when treated with IFN-γ alone or the combination of IFN-γ and IL-17 ( Figure 5c ). Blockage of Fas or TRAIL expression significantly inhibited BMMSC apoptosis (Figure 5d ). Taken together, these results collectively suggest that the Fas and TRAIL signaling pathways are important in the BMMSC apoptosis induced by IFN-γ and IL-17. Furthermore, the reduction of Fas or TRAIL could rescue osteogenic differentiation inhibited by IFN-γ and IL-17 ( Figure 5e ). Then, we found that the inhibition of caspase activity with a caspase 3 inhibitor (Z-DEVD-FMK) or a pan-caspase inhibitor (Z-VAD-FMK) could reduce the number of apoptotic cells (Figure 5f ). Moreover, blocking the caspase activity partially rescued IFN-γ-and IL-17-inhibited BMMSC osteogenesis (Figure 5g ). In summary, these observations suggest that inhibiting the apoptotic pathways can partially rescue the effects of IFN-γ and IL-17 on BMMSC differentiation. In an attempt to solve this question, we combined BMMSCs with β-TCP graft and subcutaneously implanted these into WT or IL-12p40 −/− mice. After 8 weeks, the implants were harvested (Figure 6a ). Histologic analysis showed more bone formation in the IL-12p40 −/− mice than in the WT mice (Figures 6b and c ). An immunohistochemical analysis confirmed that the depletion of IL-12 and IL-23 promoted bone formation, as shown by the marked increase in the number of Col1-positive cells in the implants of IL-12p40 −/− mice (Figures 6d and e) . Therefore, these findings indicate that IL-12 and IL-23 have important roles in BMMSC-mediated bone formation in vivo. The two cytokines can delay bone formation and impair bone healing, but the reduction of IL-12 and IL-23 can promote bone repair in vivo.
Discussion
Fracture healing can be usually divided into three overlapping phases, namely, inflammation, repair, and remodeling. 18 The early inflammatory events following fracture are critical to the final outcome of fracture healing. Immune cells are a rich source of numerous cytokines that can affect the fate of bone cells during bone remodeling and disease. However, only a limited number of studies have focused on the relationship between the immune microenvironment and bone formation. In this study, we found that the levels of IL-12 and IL-23 in the implants were higher than those of other cytokines. As IL-12 and IL-23 share the p40 subunit, we then used a mouse model with global deletion of IL-12p40 and found that IL-12p40 −/− mice stimulated bone formation and increased bone mass. Therefore, these data supported our hypothesis that IL-12 and IL-23 have important roles in bone formation in vivo. Increasing evidence has shown that IFN-γ induces cell death. 32, 33 Here, our results demonstrated that IFN-γ significantly increased BMMSC death in a dose-dependent manner. IFN-γ further caused BMMSC death in the presence of IL-17, suggesting that IL-17 synergistically promoted BMMSC death induced by IFN-γ. IFN-γ has also been shown to have a role in programmed cell death by increasing the expression of Fas/FasL and enhancing TRAIL-induced apoptosis. [34] [35] [36] Consistent with this, our study found that IFN-γ could induce BMMSC apoptosis. IL-17 synergistically enhanced IFN-γ-induced BMMSC apoptosis due to the upregulation of Fas and TRAIL expression levels in BMMSCs. Our in vitro and in vivo data indicated that the caspase cascade was activated and led to BMMSC apoptosis. In addition, our results also showed that blockage of apoptotic pathways partially rescued the inhibitory effects of IFN-γ and IL-17 on BMMSC differentiation.
Finally, we confirmed the possibility that IL-12p40 serves as a therapeutic target for inflammatory bone disorders. Strikingly, the formation of ectopic bone in the IL-12p40 −/− mice was much more than that in the WT mice, suggesting its promising potential as a therapeutic target in clinical trials. IL-12p40 neutralizing antibodies have been used to treat various immune disorders, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and Crohn's disease. 37 In the IL-12p40 impairs MSC-mediated bone regeneration via CD4 + T cells Jiajia Xu et al present paper, we showed that the expression levels of IL-12 and IL-23 were high in C57BL/6J mice and their presence could affect BMMSC-mediated bone regeneration. Depletion of IL-12p40 in mice reduced the levels of IFN-γ and IL-17, and promoted bone regeneration in vivo. Therefore, treatment with neutralizing antibodies against IL-12p40 for bone regeneration may be a feasible and effective method. We expect that IL-12p40 will be developed as a biomarker for detecting bone repair and a therapeutic target for improving therapeutic outcome of BMMSC-based bone regeneration.
Under normal physiological conditions, fracture healing is initiated by inflammation, which can clear some cellular debris and bacteria in vivo. The appropriate inflammatory cytokines stimulate the differentiation of BMMSCs into osteoblasts. However, a large number of immune cells (resident macrophages, dendritic cells, T and B cells) accumulate to the damaged tissue when severe inflammation occurs in the body. These immune cells release large amounts of proinflammatory cytokines, such as IL-12 and IL-23. Proinflammatory cytokines of the IL-12 family can upregulate the levels of IFN-γ and IL-17 in vivo. Locally produced IFN-γ and IL-17 affect the function of BMMSCs and upregulate the expression of Fas and TRAIL in BMMSCs. Increased Fas and TRAIL expression activates the caspase cascade, leading to BMMSC apoptosis and impair bone regeneration (Figure 6f) . Moreover, the inhibition of IL-12p40 can significantly promote bone repair, suggesting its promising potential as a therapeutic target.
IL-12p40 antagonists may be an ideal and safe therapeutic agent for the inflammation-mediated inhibition of bone regeneration.
Materials and Methods
Mice. B6.129S1-Il12b tm1Jm /J mice were purchased from Jackson Labs (Bar Harbor, ME, USA). Male C57BL/6J, immunocompromised nude mice (Balb/c, nu/nu) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd (Shanghai, China). The mice were housed in a specific pathogen-free animal facility of Shanghai Jiao Tong University School of Medicine. All mouse experiments were performed under protocols approved by the Institutional Animal Care and Use Committee of the Institute of Health Sciences, Shanghai Institutes for Biological Sciences, and Shanghai Jiao Tong University School of Medicine.
Isolation of mesenchymal stem cells from mouse bone marrow. Bone marrow cells from the bone cavity of femurs and tibias of mice were flushed out with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) in DMEM. All bone marrow cells were passed through a 70 μm cell strainer (BD Bioscience, San Jose, CA, USA) to obtain a single-cell suspension of all nucleated cells. All the single cells were cultured in growth medium (DMEM containing 20% FBS and 1% penicillin-streptomycin (all from Hyclone)) at 37°C in the presence of 5% CO 2 . Non-adherent cells were removed by washing the cultures with PBS twice and replacing the medium after 2 days. The attached cells were cultured and used for experiments at passage 3. Flow-cytometric analysis was conducted to confirm the characteristics of the mesenchymal stem cells. These bone marrow-derived MSCs were positive for CD44 and Sca-1 and negative for CD11b, CD11c, CD34, and CD45.
Ectopic bone formation assay. Approximately 3.0 × 10 6 of BMMSCs were mixed with β-TCP ceramic particles (45 mg, Shanghai Bio-lu Biomaterials Co., Ltd, Shanghai, China). This mixture was subcutaneously implanted into the dorsal 
